These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 8786709)

  • 1. In vitro assessment of oral delivery for hexapeptide endothelin antagonists.
    Stewart BH; Reyner EL; Tse E; Hayes RN; Werness S; He JX; Cody WL; Doherty AM
    Life Sci; 1996; 58(12):971-82. PubMed ID: 8786709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of a potent combined pseudopeptide endothelin-A/endothelin-B receptor antagonist, Ac-DBhg16-Leu-Asp-Ile-[NMe]Ile-Trp21 (PD 156252): examination of its pharmacokinetic and spectral properties.
    Cody WL; He JX; Reily MD; Haleen SJ; Walker DM; Reyner EL; Stewart BH; Doherty AM
    J Med Chem; 1997 Jul; 40(14):2228-40. PubMed ID: 9216842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of the potent combined endothelin-A/endothelin-B receptor antagonist Ac-DDip16-Leu-Asp-Ile-Ile-Trp21: development of endothelin-B receptor selective antagonists.
    Cody WL; He JX; DePue PL; Waite LA; Leonard DM; Sefler AM; Kaltenbronn JS; Haleen SJ; Walker DM; Flynn MA
    J Med Chem; 1995 Jul; 38(15):2809-19. PubMed ID: 7636842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists.
    Doherty AM; Cody WL; He JX; DePue PL; Cheng XM; Welch KM; Flynn MA; Reynolds EE; LaDouceur DM; Davis LS
    J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S98-102. PubMed ID: 7510009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro stability and intestinal absorption characteristics of hexapeptide endothelin receptor antagonists.
    Han HK; Stewart BH; Doherty AM; Cody WL; Amidon GL
    Life Sci; 1998; 63(18):1599-609. PubMed ID: 9806213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065.
    Warner TD; Allcock GH; Vane JR
    Br J Pharmacol; 1994 May; 112(1):207-13. PubMed ID: 8032643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model.
    Macchia M; Barontini S; Ceccarelli F; Galoppini C; Giusti L; Hamdan M; Lucacchini A; Martinelli A; Menchini E; Mazzoni MR; Revoltella RP; Romagnoli F; Rovero P
    Farmaco; 1998; 53(8-9):545-56. PubMed ID: 10081817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of renal and systemic responses to endothelin-1 infusion with PD 145065.
    Wellings RP; Corder R; Doherty AM; Vane JR
    Eur J Pharmacol; 1994 Apr; 256(2):201-4. PubMed ID: 8050471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF.
    Warner TD; Allcock GH; Corder R; Vane JR
    Br J Pharmacol; 1993 Oct; 110(2):777-82. PubMed ID: 8242251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin-1-evoked calcium transients in UMR-106 osteoblastic osteosarcoma cells are mediated through endothelin-A and endothelin-B receptors.
    Semler DE; Ohlstein EH; Nambi P; Slater C; Stern PH
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1052-8. PubMed ID: 7891315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexapeptide and cyclic pentapeptide endothelin antagonists directly activate pituitary gonadotropin-releasing hormone receptors.
    Yahalom D; Koch Y; Ben-Aroya N; Fridkin M
    Mol Pharmacol; 2000 Apr; 57(4):718-24. PubMed ID: 10727517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.
    Wellings RP; Corder R; Warner TD; Cristol JP; Thiemermann C; Vane JR
    Br J Pharmacol; 1994 Feb; 111(2):515-20. PubMed ID: 8004396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of ETB receptors limits the efficacy of nonselective endothelin antagonists in vivo.
    Allcock GH; Warner TD
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S177-9. PubMed ID: 8587355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of endothelin receptors in the regional and systemic vascular responses to ET-1 in the anaesthetized ganglion-blocked rat: use of selective antagonists.
    Allcock GH; Warner TD; Vane JR
    Br J Pharmacol; 1995 Nov; 116(5):2482-6. PubMed ID: 8581288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ca2+ signalling by endothelin receptors in rat and human cultured airway smooth muscle cells.
    Maxwell MJ; Goldie RG; Henry PJ
    Br J Pharmacol; 1998 Dec; 125(8):1768-78. PubMed ID: 9886769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1[1-31] acts as a selective ETA-receptor agonist in the rat adrenal cortex.
    Rebuffat P; Malendowicz LK; Neri G; Nussdorfer GG
    Histol Histopathol; 2001 Apr; 16(2):535-40. PubMed ID: 11332709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin ET
    Vercauteren M; Trensz F; Pasquali A; Cattaneo C; Strasser DS; Hess P; Iglarz M; Clozel M
    J Pharmacol Exp Ther; 2017 May; 361(2):322-333. PubMed ID: 28223322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin-induced nociception in mice: mediation by ETA and ETB receptors.
    Raffa RB; Schupsky JJ; Jacoby HI
    J Pharmacol Exp Ther; 1996 Feb; 276(2):647-51. PubMed ID: 8632332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclic hexapeptide endothelin receptor antagonists highly potent for both receptor subtypes ETA and ETB.
    Kikuchi T; Ohtaki T; Kawata A; Imada T; Asami T; Masuda Y; Sugo T; Kusumoto K; Kubo K; Watanabe T
    Biochem Biophys Res Commun; 1994 May; 200(3):1708-12. PubMed ID: 8185629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.